View in EDS HTML Full Text

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Saved in:
Bibliographic Details
Title: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Authors: Black DM (AUTHOR), Cummings SR (AUTHOR), Karpf DB (AUTHOR), Cauley JA (AUTHOR), Thompson DE (AUTHOR), Nevitt MC (AUTHOR), Bauer DC (AUTHOR), Genant HK (AUTHOR), Haskell WL (AUTHOR), Marcus R (AUTHOR), Ott SM (AUTHOR), Torner JC (AUTHOR), Quandt SA (AUTHOR), Reiss TF (AUTHOR), Ensrud KE (AUTHOR), Fracture Intervention Trial Research Group (CORPORATE AUTHOR), Black, D M (AUTHOR), Cummings, S R (AUTHOR), Karpf, D B (AUTHOR), Cauley, J A (AUTHOR)
Source: Lancet. 12/7/1996, Vol. 348 Issue 9041, p1535-1541. 7p.
Abstract: Background: Previous studies have shown that alendronate can increase bone mineral density (BMD) and prevent radiographically defined (morphometric) vertebral fractures. The Fracture Intervention Trial aimed to investigate the effect of alendronate on the risk of morphometric as well as clinically evident fractures in postmenopausal women with low bone mass.Methods: Women aged 55-81 with low femoral-neck BMD were enrolled in two study groups based on presence or absence of an existing vertebral fracture. Results for women with at least one vertebral fracture at baseline are reported here. 2027 women were randomly assigned placebo (1005) or alendronate (1022) and followed up for 36 months. The dose of alendronate (initially 5 mg daily) was increased (to 10 mg daily) at 24 months, with maintenance of the double blind. Lateral spine radiography was done at baseline and at 24 and 36 months. New vertebral fractures, the primary endpoint, were defined by morphometry as a decrease of 20% (and at least 4 mm) in at least one vertebral height between the baseline and latest follow-up radiograph. Non-spine clinical fractures were confirmed by radiographic reports. New symptomatic vertebral fractures were based on self-report and confirmed by radiography.Findings: Follow-up radiographs were obtained for 1946 women (98% of surviving participants). 78 (8.0%) of women in the alendronate group had one or more new morphometric vertebral fractures compared with 145 (15.0%) in the placebo group (relative risk 0.53 [95% Cl 0.41-0.68]). For clinically apparent vertebral fractures, the corresponding numbers were 23 (2.3%) alendronate and 50 (5.0%) placebo (relative hazard 0.45 [0.27-0.72]). The risk of any clinical fracture, the main secondary endpoint, was lower in the alendronate than in the placebo group (139 [13.6%] vs 183 [18.2%]; relative hazard 0.72 [0.58-0.90]). The relative hazards for hip fracture and wrist fracture for alendronate versus placebo were 0.49 (0.23-0.99) and 0.52 (0.31-0.87). There was no significant difference between the groups in numbers of adverse experiences, including upper-gastrointestinal disorders.Interpretation: We conclude that among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebral fractures, as well as other clinical fractures. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 107278183
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Black+DM%22">Black DM</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cummings+SR%22">Cummings SR</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Karpf+DB%22">Karpf DB</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cauley+JA%22">Cauley JA</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Thompson+DE%22">Thompson DE</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nevitt+MC%22">Nevitt MC</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bauer+DC%22">Bauer DC</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Genant+HK%22">Genant HK</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Haskell+WL%22">Haskell WL</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Marcus+R%22">Marcus R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ott+SM%22">Ott SM</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Torner+JC%22">Torner JC</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Quandt+SA%22">Quandt SA</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Reiss+TF%22">Reiss TF</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ensrud+KE%22">Ensrud KE</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fracture+Intervention+Trial+Research+Group%22">Fracture Intervention Trial Research Group</searchLink> (CORPORATE AUTHOR)<br /><searchLink fieldCode="AR" term="%22Black%2C+D+M%22">Black, D M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cummings%2C+S+R%22">Cummings, S R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Karpf%2C+D+B%22">Karpf, D B</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cauley%2C+J+A%22">Cauley, J A</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 12/7/1996, Vol. 348 Issue 9041, p1535-1541. 7p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Previous studies have shown that alendronate can increase bone mineral density (BMD) and prevent radiographically defined (morphometric) vertebral fractures. The Fracture Intervention Trial aimed to investigate the effect of alendronate on the risk of morphometric as well as clinically evident fractures in postmenopausal women with low bone mass.<bold>Methods: </bold>Women aged 55-81 with low femoral-neck BMD were enrolled in two study groups based on presence or absence of an existing vertebral fracture. Results for women with at least one vertebral fracture at baseline are reported here. 2027 women were randomly assigned placebo (1005) or alendronate (1022) and followed up for 36 months. The dose of alendronate (initially 5 mg daily) was increased (to 10 mg daily) at 24 months, with maintenance of the double blind. Lateral spine radiography was done at baseline and at 24 and 36 months. New vertebral fractures, the primary endpoint, were defined by morphometry as a decrease of 20% (and at least 4 mm) in at least one vertebral height between the baseline and latest follow-up radiograph. Non-spine clinical fractures were confirmed by radiographic reports. New symptomatic vertebral fractures were based on self-report and confirmed by radiography.<bold>Findings: </bold>Follow-up radiographs were obtained for 1946 women (98% of surviving participants). 78 (8.0%) of women in the alendronate group had one or more new morphometric vertebral fractures compared with 145 (15.0%) in the placebo group (relative risk 0.53 [95% Cl 0.41-0.68]). For clinically apparent vertebral fractures, the corresponding numbers were 23 (2.3%) alendronate and 50 (5.0%) placebo (relative hazard 0.45 [0.27-0.72]). The risk of any clinical fracture, the main secondary endpoint, was lower in the alendronate than in the placebo group (139 [13.6%] vs 183 [18.2%]; relative hazard 0.72 [0.58-0.90]). The relative hazards for hip fracture and wrist fracture for alendronate versus placebo were 0.49 (0.23-0.99) and 0.52 (0.31-0.87). There was no significant difference between the groups in numbers of adverse experiences, including upper-gastrointestinal disorders.<bold>Interpretation: </bold>We conclude that among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebral fractures, as well as other clinical fractures. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=107278183
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/s0140-6736(96)07088-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 1535
    Titles:
      – TitleFull: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Black DM
      – PersonEntity:
          Name:
            NameFull: Cummings SR
      – PersonEntity:
          Name:
            NameFull: Karpf DB
      – PersonEntity:
          Name:
            NameFull: Cauley JA
      – PersonEntity:
          Name:
            NameFull: Thompson DE
      – PersonEntity:
          Name:
            NameFull: Nevitt MC
      – PersonEntity:
          Name:
            NameFull: Bauer DC
      – PersonEntity:
          Name:
            NameFull: Genant HK
      – PersonEntity:
          Name:
            NameFull: Haskell WL
      – PersonEntity:
          Name:
            NameFull: Marcus R
      – PersonEntity:
          Name:
            NameFull: Ott SM
      – PersonEntity:
          Name:
            NameFull: Torner JC
      – PersonEntity:
          Name:
            NameFull: Quandt SA
      – PersonEntity:
          Name:
            NameFull: Reiss TF
      – PersonEntity:
          Name:
            NameFull: Ensrud KE
      – PersonEntity:
          Name:
            NameFull: Fracture Intervention Trial Research Group
      – PersonEntity:
          Name:
            NameFull: Black, D M
      – PersonEntity:
          Name:
            NameFull: Cummings, S R
      – PersonEntity:
          Name:
            NameFull: Karpf, D B
      – PersonEntity:
          Name:
            NameFull: Cauley, J A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 12
              Text: 12/7/1996
              Type: published
              Y: 1996
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 348
            – Type: issue
              Value: 9041
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1